-
11.发明公开公开(公告)号：US20240293456A1
公开(公告)日：2024-09-05
申请号：US18255094
申请日：2021-11-29
Applicant: PURDUE RESEARCH FOUNDATION
Inventor： Philip S. LOW , Weichuan LOU
CPC classification number: A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464412 , A61K47/551 , C07K16/2803 , A61K2239/13 , A61K2239/49
Abstract: A combination cancer therapy comprising a small molecule drug conjugate (SMDC), which targets a cell-surface receptor on an immunosuppressive cell or a cancerous cell, and cytotoxic lymphocytes, which express a chimeric antigen receptor (CAR); and a method of treating a patient for cancer using the same.
-
公开(公告)号：US20160287731A1
公开(公告)日：2016-10-06
申请号：US15035936
申请日：2014-11-13
Applicant: ENDOCYTE, INC. , PURDUE RESEARCH FOUNDATION
Inventor： Iontcho R. VLAHOV , Christopher P. LEAMON , Philip S. LOW , Garth L PARHAM , Qingshou CHEN
CPC classification number: A61K51/0497 , A61K51/04 , A61K51/0482
Abstract: Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
Abstract translation: 本文描述了使用正电子发射断层摄影技术诊断和/或监测致病性疾病的化合物，组合物和方法。 还描述了式B-L-P的缀合物，其中B是选自维生素受体结合配体（如叶酸），PSMA结合配体或PSMA抑制剂的靶向剂的基团; L是包含天冬氨酸，赖氨酸或精氨酸的二价连接体，P是显像剂或放射治疗剂的基团，例如含有放射性核素或放射性核素的基团，或能够结合放射性核素的化合物的基团，例如 金属螯合基团。
-
公开(公告)号：US20160207999A1
公开(公告)日：2016-07-21
申请号：US15094211
申请日：2016-04-08
Applicant: PURDUE RESEARCH FOUNDATION , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI
Inventor： Philip S. LOW , Dimiter S. DIMITROV , Yang FENG , Jiayin SHEN
IPC: C07K16/28
CPC classification number: C07K16/28 , A61K9/0019 , A61K9/127 , A61K38/00 , A61K47/6849 , A61K47/6911 , A61K47/6913 , A61K49/0058 , A61K49/16 , A61K51/1027 , C07K14/705 , C07K2317/21 , C07K2317/33 , C07K2317/54 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ.
-
公开(公告)号：US20140065066A1
公开(公告)日：2014-03-06
申请号：US13793654
申请日：2013-03-11
Applicant: PURDUE RESEARCH FOUNDATION
Inventor： Philip S. LOW , Andrew R. HILGENBRINK
CPC classification number: A61K51/044 , A61K38/19 , A61K38/47 , A61K47/545 , A61K47/551 , A61K47/64 , A61K47/6911 , A61K49/0021 , A61K49/0041 , A61K49/0043 , A61K49/0052 , A61K51/0459 , C09B11/24
Abstract: The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formula Ab-X wherein the group Ab comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the disease state, the group X comprises an imaging agent.
Abstract translation: 本发明涉及一种治疗或诊断由单核细胞介导的疾病状态的方法。 该方法使用包含通式Ab-X的缀合物或复合物的组合物，其中基团Ab包含与单核细胞结合的配体，当缀合物用于治疗疾病状态时，组X包含免疫原， 细胞毒素或能够改变单核细胞功能的化合物，当共轭物用于诊断疾病状态时，组X包含成像剂。
-
公开(公告)号：US20240316224A1
公开(公告)日：2024-09-26
申请号：US18436484
申请日：2024-02-08
Applicant: Purdue Research Foundation
Inventor： Philip S. LOW , Pengcheng LU
CPC classification number: A61K51/0497 , A61K47/60 , A61K47/65 , A61K49/0032 , A61K49/0041 , A61K51/04 , A61K2123/00
Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in SPECT imaging methods.
-
Patent Agency Ranking
公开(公告)号：US20190083663A1
公开(公告)日：2019-03-21
申请号：US16085393
申请日：2017-03-16
Applicant: Purdue Research Foundation
Inventor： Philip S. LOW , Pengcheng LU
Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in SPECT imaging methods.
-
公开(公告)号：US20180271990A1
公开(公告)日：2018-09-27
申请号：US15990152
申请日：2018-05-25
Applicant: Purdue Research Foundation
Inventor： Philip S. LOW , Sumith A. KULARATNE
IPC: A61K47/64 , A61K31/426 , A61K49/00 , A61K31/475 , C07D207/416 , C07C323/52 , C07K5/08 , A61K51/04 , A61K31/4745 , A61K47/54 , A61K51/08
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
-
公开(公告)号：US20180271988A1
公开(公告)日：2018-09-27
申请号：US15990083
申请日：2018-05-25
Applicant: Purdue Research Foundation
Inventor： Philip S. LOW , Sumith A. KULARATNE
IPC: A61K47/64 , A61K31/426 , A61K49/00 , A61K31/475 , C07D207/416 , C07C323/52 , C07K5/08 , A61K51/04 , A61K31/4745 , A61K47/54 , A61K51/08
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
-
公开(公告)号：US20180251544A1
公开(公告)日：2018-09-06
申请号：US15970352
申请日：2018-05-03
Applicant: PURDUE RESEARCH FOUNDATION , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HE
Inventor： Philip S. LOW , Dimiter S. DIMITROV , Yang FENG , Jiayin SHEN
IPC: C07K16/28 , A61K9/00 , A61K47/69 , A61K47/68 , A61K9/127 , A61K38/00 , A61K49/00 , A61K49/16 , A61K51/10 , C07K14/705
CPC classification number: C07K16/28 , A61K9/0019 , A61K9/127 , A61K38/00 , A61K47/6849 , A61K47/6911 , A61K47/6913 , A61K49/0058 , A61K49/16 , A61K51/1027 , C07K14/705 , C07K2317/21 , C07K2317/33 , C07K2317/54 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as method of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ.
-
公开(公告)号：US20170216465A1
公开(公告)日：2017-08-03
申请号：US15501630
申请日：2015-08-07
Applicant: PURDUE RESEARCH FOUNDATION
Inventor： Ananda Kumar KANDULURU , Philip S. LOW
CPC classification number: A61K51/0459 , A61K31/404 , A61K31/4545 , A61K31/475 , A61K38/05 , A61K49/0041 , A61K49/0052 , A61K51/0455 , A61K51/0478 , A61K51/0482 , A61K51/06 , A61K51/08 , C07K14/70571 , C09B11/24 , C09B23/0025 , C09B23/0066
Abstract: Neurokinin-1 (NK-1) receptor-binding agent delivery conjugates, compositions comprising NK-1 receptor-binding agent delivery conjugates, and methods for making and administering NK-1 receptor-binding agent delivery conjugates are provided. A conjugate may include an NK-1 receptor-binding moiety, a linker group containing at least one linker selected from the group of a releasable linker and a spacer linker, and an active agent linked to the linker group. The active agent may be selected from the group of fluorophore-containing compounds, radionuclide-containing compounds, and therapeutic agents for treatment of tumor cells characterized by over-expression of the NK-1 receptor.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.018 seconds)
